Research map: Adaptive dosing of immunotherapy plus anti-angiogenic therapy in a nonagenarian with hepatocellular carcinoma: a case report with 10-year survival

Back to the article

Papers in this map

  1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma · Richard S. Finn · 2020 · 7562 citations · Cited by this paper
  2. Contrast-enhanced ultrasound-guided biopsy and perfusion monitoring for bladder involvement in relapsed multiple myeloma: a case report · 2026 · Related
  3. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy · Yuhui Huang · 2012 · 1116 citations · Cited by this paper
  4. Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities · 2026 · Related
  5. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions · Mina S. Sedrak · 2020 · 493 citations · Cited by this paper
  6. Predictors and prevalence of lateral supraclavicular lymph node metastases on [18F]FDG PET/CT in patients with locally advanced, or multifocal invasive ductal carcinoma of breast: potential impact on adjuvant radiotherapy targets · 2026 · Related
  7. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies · Azael Freites‐Martínez · 2020 · 229 citations · Cited by this paper
  8. Case Report: a hypermetabolic mediastinal mass (SUVmax 16.7) mimicking malignancy with spontaneous resolution: an inflammatory myofibroblastic proliferation and diagnostic pitfall · 2026 · Related
  9. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial · Shukui Qin · 2022 · 195 citations · Cited by this paper
  10. Variations in histopathological and molecular subtypes between primary breast carcinoma and associated liver metastatic lesions · 2026 · Related
  11. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial · Daneng Li · 2022 · 41 citations · Cited by this paper
  12. Concurrent icotinib and definitive radiotherapy followed by detection of an EGFR exon 20 insertion at disease progression in unresectable stage III EGFR S768I-mutant lung adenocarcinoma: a case report · 2026 · Related
  13. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential · Jing Lin Tong · 2025 · 36 citations · Cited by this paper
  14. Perioperative outcomes and prognostic determinants in adult spindle cell/sclerosing rhabdomyosarcoma: implications of treatment intensity, surgical margins, and molecular heterogeneity · 2026 · Related
  15. A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394 · Shukui Qin · 2024 · 14 citations · Cited by this paper
  16. The combined compartmental maxillary resection: technique codification and preliminary multicenter series analysis · 2026 · Related
  17. “Start low, go slow,” a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis · Gabriel Francisco Pereira Aleixo · 2024 · 11 citations · Cited by this paper
  18. Baseline 18F-FDG PET/CT metabolic parameters and systemic inflammatory markers in advanced NSCLC treated with first-line immunotherapy: an exploratory retrospective analysis · 2026 · Related
  19. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis · Cheng‐Long Han · 2024 · 10 citations · Cited by this paper
  20. Enhancing multimodal survival prediction: tri-modal learning with clinical knowledge integration via state space models · 2026 · Related
  21. Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study · Lushan Xiao · 2023 · 8 citations · Cited by this paper
  22. Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma · Dimity Ball · 2025 · 7 citations · Cited by this paper
  23. Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden · Ming‐Cheng Guan · 2025 · 4 citations · Cited by this paper
  24. Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study · Francesco Tovoli · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)